Wet age-related macular degeneration is the leading cause of blindness in the older U.S. population. It is estimated that there are about 1.6 million people with wet AMD in the U.S. There are several approved treatments for wet AMD, mostly in the form of anti-VEGF eye injections. These include Roche's Lucentis and Vabysmo; Regeneron's Eylea and Eylea HD; and Novartis' Beovu. There are also approved biosimilar drugs, such as Byooviz from Samsung Bioepis and Biogen, and Cimerli from Coherus BioSciences, for wet AMD.
The stock we are bringing to your attention today is that of Ocular Therapeutix Inc. (OCUL), which is also developing a treatment for wet AMD.
For comments and feedback contact: editorial@rttnews.com
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.